BioVex Group, Inc.
http://www.biovex.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From BioVex Group, Inc.
Incyte To Seek Another Monjuvi Approval In Crowded CD19-Targeting Market
Incyte reported positive topline Phase III results for Monjuvi in relapsed or refractory follicular lymphoma and plans to file for US FDA approval by the end of 2024.
Merck Steps Into CD19 Bispecific Antibody Ring With Curon Deal
The drug maker is spending up to $1.3bn to acquire rights to CN201, a CD19xCD3-directed bispecific antibody that it plans to develop for B-cell malignancies and autoimmune diseases.
J&J To Launch Velys Spine Platform After Securing FDA Clearance
J&J Medtech announced the FDA clearance of its dual-use robotics platform Velys Spine with plans to go to market in the first half of 2025.
Finance Watch: Two New VC Funds Bring $365m For Start-Ups
Private Company Edition: Amplitude Ventures raised $192m for its second fund, while XGEN Venture debuted with €160m ($173.4m). Also, hub-and-spoke biopharma operator CinRx added $73m, Adcendo extended its series A round to €98m ($106.2m) and Grey Wolf raised $50m.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Drug Delivery
- Macromolecule
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
-
Drug Discovery Tools
- Genomics-Proteomics
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice